학술논문
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Document Type
article
Author
Magaret, Craig; Li, Li; deCamp, Allan; Rolland, Morgane; Juraska, Michal; Williamson, Brian; Ludwig, James; Molitor, Cindy; Benkeser, David; Luedtke, Alex; Simpkins, Brian; Heng, Fei; Sun, Yanqing; Carpp, Lindsay; Bai, Hongjun; Dearlove, Bethany; Giorgi, Elena; Jongeneelen, Mandy; Brandenburg, Boerries; McCallum, Matthew; Bowen, John; Veesler, David; Sadoff, Jerald; Gray, Glenda; Roels, Sanne; Vandebosch, An; Stieh, Daniel; Le Gars, Mathieu; Vingerhoets, Johan; Grinsztejn, Beatriz; Goepfert, Paul; de Sousa, Leonardo; Silva, Mayara; Casapia, Martin; Losso, Marcelo; Gaur, Aditya; Bekker, Linda-Gail; Garrett, Nigel; Truyers, Carla; Van Dromme, Ilse; Swann, Edith; Marovich, Mary; Follmann, Dean; Neuzil, Kathleen; Corey, Lawrence; Greninger, Alexander; Roychoudhury, Pavitra; Hyrien, Ollivier; Gilbert, Peter; Little, Susan
Source
Nature Communications. 15(1)
Subject
Language
Abstract
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p